What ten-year success rates look like for OATS patients

Across the published evidence in young, active patients, ten-year success rates for OATS mosaicplasty sit broadly in the range of 72–89%. For those who are the best candidates — typically under 40, with a lesion smaller than 3 cm² on the femoral condyle — failure rates fall as low as 12.5–14%. In older patients or those with larger defects, that figure can rise to 38–40%.

The firmest direct evidence comes from Gudas et al. (American Journal of Sports Medicine, 2012), the only prospective randomised controlled trial to reach a full ten years of follow-up: OATS produced a substantially lower failure rate than microfracture in young athletes, a finding corroborated at the population level by Muthu et al.'s 2024 network meta-analysis drawing on a broader pool of comparative studies.

Those headline figures, though, carry an important caveat: 'success' is not defined the same way across studies. Some trials measure it through patient-reported functional scores, others through return to sport, and others through avoidance of arthroplasty — and each dimension tells a somewhat different story. Individual studies are also modest in size, which limits how precisely any single number can be applied to an individual patient. The sections below work through each of those dimensions in turn, starting with the functional score evidence and moving through athletic return, reoperation risk, and the patient factors most likely to predict a good result.

What OATS mosaicplasty involves

OATS mosaicplasty is a single-stage procedure in which small cylindrical plugs of healthy bone and cartilage — taken from a low-load area of the patient's own knee — are transplanted directly into the damaged site during the same operation. Because the tissue comes from the patient, there is no donor waiting list and no cell-culture stage; the repair is completed in one surgical episode.

The 'mosaic' name refers to what happens when multiple plugs are used side by side to fill a larger defect. A single-plug transfer typically covers a lesion of roughly 1–2 cm²; arranging several plugs in a mosaic pattern can extend coverage to around 4 cm². The procedure is indicated for focal, full-thickness cartilage loss — ICRS Grade III or IV — most commonly on the femoral condyle, where grafts tend to integrate most predictably.

One limitation worth knowing before considering the technique is donor-site morbidity. When graft material is taken from a donor site, approximately 14% of patients report persistent knee pain at that harvest location during long-term follow-up. That figure comes from ankle-graft recipients and may not apply uniformly across all harvest configurations, but it is a recognised trade-off that any pre-operative conversation should address.

This single-stage, fully autologous character distinguishes OATS from two-stage cell-based techniques such as ACI or MACI, which require an initial biopsy, a laboratory culture period of several weeks, and a second surgical implantation — context that helps frame the outcome data discussed below.

Functional scores and reoperation over ten years

The 2024 institutional registry of 63 patients — mean age 27.4 years — gives the most detailed picture of how functional scores evolve over a decade. IKDC scores (a 0–100 scale measuring knee symptoms and activity) improved from 46.4 before surgery to 70.4 at ten years; KOS-ADL (activities of daily living function, also 0–100) rose from 64.4 to 83.8. Both shifts are clinically substantial.

More telling than the raw numbers is the proportion of patients who crossed the MCID — the minimum clinically important difference, meaning the threshold at which improvement becomes meaningful to the patient rather than merely detectable by statistics. At ten years, 60% of patients surpassed the IKDC MCID, compared with 69% at two years. The modest decline over time indicates that gains are real and sustained for the majority, but that a subset experiences gradual attenuation as the years pass.

The reoperation rate of 28.6% warrants careful reading: the predominant procedures were partial meniscectomy, chondroplasty, and loose body removal — all relatively minor arthroscopic interventions typically occurring at a mean of around 43 months post-surgery. Conversion to arthroplasty, by contrast, occurred in just two patients (3.2%). Those are clinically very different events, and the distinction matters considerably when weighing long-term risk.

On durability beyond ten years, Keszég et al. (2022) followed patients for between 10 and 25 years and found no significant deterioration in functional scores even after the twenty-year mark — the longest published follow-up available for this procedure. The series is not large, and individual outcomes vary, but the trajectory is broadly reassuring for younger patients planning their surgical options.

Return-to-sport rates for athletes

For athletes weighing their options, the headline figure from a 2023 scoping review of 16 studies is a return-to-sport rate of 87–100% after osteochondral autograft transfer — the highest range recorded across all cartilage repair procedures reviewed, above both microfracture (44–83%) and ACI (33–96%). The more meaningful measure for most competitors, however, is return to their preinjury level of sport, which the same review places at 67–93%. That wider range acknowledges that getting back on the pitch is not the same as getting back to the level you left.

Competitive football offers a useful concrete example: 83% of players treated with OAT returned to competitive soccer, and 80% returned to the same competitive tier. For elite athletes specifically, synthesis estimates approach 89% success at ten years — figures that sit toward the upper end of the broader population range.

One dimension the literature handles less cleanly is timing. Return-to-sport timelines vary enough between series — reflecting differences in lesion size, rehabilitation protocols, and sport type — that quoting a single reliable figure would misrepresent the evidence. A treating clinician, working from an individual's imaging, surgical findings, and sport demands, is the appropriate source for a realistic timeline.

The two factors that most consistently predict reaching preinjury sport level are explored in the next section.

Who gets the best results — and who is not a good candidate

Three variables reliably sort candidates into stronger and weaker prognostic groups: age, lesion size, and anatomical location.

Published series consistently identify patients under 25 with lesions below 2 cm² as the group achieving the strongest outcomes. Femoral condyle defects respond more predictably than those on the patella or trochlea, where contact mechanics place greater demands on graft integration. In optimal candidates — younger age, smaller defect, condylar site — failure rates in published series sit around 12.5–14%. In older patients or those with defects above 3 cm², that figure rises to roughly 38–40%: approximately three times higher.

Certain characteristics place OATS outside realistic consideration. A BMI above 40, age above 50, or osteoarthritis beyond Kellgren-Lawrence Grade 2 are recognised relative contraindications; the procedure depends on a joint environment capable of supporting graft survival and functional remodelling. Prior inflammatory arthritis or a history of joint infection carry similar cautions.

One planning insight worth stating plainly: a strong two-year result — whether measured by MRI appearance or functional score — should not be taken as a guarantee of ten-year durability. The Gudas trial found outcomes in both groups looking broadly comparable at short-term follow-up; meaningful divergence only appeared between years five and ten, as microfracture declined while OATS held stable. Which side of those prognostic thresholds a patient sits on, and what their interim data actually signals for the decade ahead, is a question to work through with a specialist rather than assume from early findings alone.

How OATS compares to other cartilage repair options

Placing OATS in context means comparing it against the procedures patients are most likely to encounter: microfracture historically, and MACI or AMIC in contemporary practice.

The clearest quantitative separation is against microfracture at ten years. In the Gudas 2012 RCT, OATS produced a 14% failure rate against 38% for microfracture in young athletes (P<0.05), with divergence emerging only between years five and ten — not at short-term follow-up, when results in both groups looked broadly similar. The mechanism behind that late decline is fibrocartilage breakdown under repeated athletic load, compounded by subchondral bone plate damage that complicates any subsequent repair attempt. NICE's evidence overview HTG463 assessed this comparison at ten years, lending regulatory-level scrutiny to the finding.

Head-to-head data comparing OATS with MACI at ten years is limited, so the comparison is approximate. At 10–17 years, MACI shows 7.4% progression to TKA and 9.0% all-cause reoperation — a reference point worth noting, with the caveat that patient populations and defect profiles differ between series. MACI is generally favoured for larger defects (2–10 cm²) where autograft plug volume becomes a practical constraint; for posttraumatic cases or defects above 4 cm², osteochondral allograft (OCA) may be the more appropriate option still.

For patients with specific concerns about donor-site morbidity, AMIC (matrix-augmented microfracture) offers a single-stage alternative without plug harvesting, though its ten-year outcome data remain less established than those available for OATS.

The evidence is firmest for OATS in young patients with focal femoral condyle defects — the precise setting of the Gudas trial and the population where the ten-year advantage is most clearly demonstrated. Which of these pathways is appropriate for a given presentation depends on defect size, joint condition, and individual circumstances: a question for specialist assessment. Search MSK lists knee cartilage specialists across the UK who offer OATS and the alternative procedures described here, searchable by region and specialty.